Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Hypermethylation of testis derived transcript gene promoter significantly correlates with worse outcomes in glioblastoma patients.

Wang LJ, Bai Y, Bao ZS, Chen Y, Yan ZH, Zhang W, Zhang QG.

Chin Med J (Engl). 2013;126(11):2062-6.

PMID:
23769558
[PubMed - indexed for MEDLINE]
Free Article
2.

Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.

Skiriutė D, Vaitkienė P, Ašmonienė V, Steponaitis G, Deltuva VP, Tamašauskas A.

J Neurooncol. 2013 Jul;113(3):441-9. doi: 10.1007/s11060-013-1133-3. Epub 2013 Apr 28.

PMID:
23624749
[PubMed - indexed for MEDLINE]
3.

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.

J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.

PMID:
23245659
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
[PubMed - indexed for MEDLINE]
5.

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.

Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E, Lopes JM, Costa P, Damasceno M, Reis RM.

Oncol Rep. 2010 Jun;23(6):1655-62.

PMID:
20428822
[PubMed - indexed for MEDLINE]
6.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R.

Clin Cancer Res. 2004 Mar 15;10(6):1871-4.

PMID:
15041700
[PubMed - indexed for MEDLINE]
Free Article
7.

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T.

Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.

PMID:
20232102
[PubMed - indexed for MEDLINE]
8.

Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.

Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN.

Oncogene. 2007 Jan 25;26(4):583-93. Epub 2006 Aug 14.

PMID:
16909125
[PubMed - indexed for MEDLINE]
9.

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.

Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T.

PLoS One. 2011;6(8):e23332. doi: 10.1371/journal.pone.0023332. Epub 2011 Aug 4.

PMID:
21829728
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines.

Kadowaki M, Yoshioka H, Kamitani H, Watanabe T, Wade PA, Eling TE.

Int J Cancer. 2012 Jan 15;130(2):267-77. doi: 10.1002/ijc.26082. Epub 2011 May 25.

PMID:
21437897
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.

Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS, Hamada J.

Carcinogenesis. 2013 Oct;34(10):2206-17. doi: 10.1093/carcin/bgt182. Epub 2013 May 28.

PMID:
23715499
[PubMed - indexed for MEDLINE]
12.

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.

SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y.

Cancer Sci. 2012 Feb;103(2):269-73. doi: 10.1111/j.1349-7006.2011.02134.x. Epub 2011 Nov 28.

PMID:
22034964
[PubMed - indexed for MEDLINE]
13.

[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].

Zheng CQ, Ji SP, Gong F, Li AM, Tai JL, Zhang YP.

Ai Zheng. 2009 Jun;28(6):575-80. Chinese.

PMID:
19635193
[PubMed - indexed for MEDLINE]
14.

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME.

Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Erratum in: Acta Neuropathol. 2013 Jul;126(1):159.

PMID:
22810491
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.

N Engl J Med. 2005 Mar 10;352(10):997-1003.

PMID:
15758010
[PubMed - indexed for MEDLINE]
Free Article
16.

Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.

Koutsimpelas D, Pongsapich W, Heinrich U, Mann S, Mann WJ, Brieger J.

Oncol Rep. 2012 Apr;27(4):1135-41. doi: 10.3892/or.2012.1624. Epub 2012 Jan 9.

PMID:
22246327
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.

Ramakrishnan V, Kushwaha D, Koay DC, Reddy H, Mao Y, Zhou L, Ng K, Zinn P, Carter B, Chen CC.

Cancer Biomark. 2011-2012;10(3-4):185-93. doi: 10.3233/CBM-2012-0245.

PMID:
22674304
[PubMed - indexed for MEDLINE]
18.

Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.

Mossman D, Kim KT, Scott RJ.

BMC Cancer. 2010 Jul 12;10:366. doi: 10.1186/1471-2407-10-366.

PMID:
20618997
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.

Uno M, Oba-Shinjo SM, Camargo AA, Moura RP, Aguiar PH, Cabrera HN, Begnami M, Rosemberg S, Teixeira MJ, Marie SK.

Clinics (Sao Paulo). 2011;66(10):1747-55.

PMID:
22012047
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.

Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.

J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.

PMID:
19011762
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk